 Anavex Life Sciences Corp NASDAQ: AVXL announced topline results from its Phase 1 trial of ANAVEX3-71 in development for neurodegenerative diseases, including Frontotemporal Dementia FTD. ANAVEX3-71 was well tolerated in all cohorts receiving single doses of the treatment candidate ranging from 5 mg to 200 mg daily with no serious adverse events SAEs and no significant lab abnormalities in any subject. 